134 related articles for article (PubMed ID: 25109698)
1. NRP-1 expression is strongly associated with the progression of pituitary adenomas.
Lee SW; Lee JE; Yoo CY; Ko MS; Park CS; Yang SH
Oncol Rep; 2014 Oct; 32(4):1537-42. PubMed ID: 25109698
[TBL] [Abstract][Full Text] [Related]
2. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
5. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
6. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
7. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
8. Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.
Bernatz S; Monden D; Gessler F; Radic T; Hattingen E; Senft C; Seifert V; Ronellenfitsch MW; Plate KH; Harter PN; Baumgarten P
J Mol Histol; 2021 Apr; 52(2):233-243. PubMed ID: 33528717
[TBL] [Abstract][Full Text] [Related]
9. Recurrence in pituitary adenomas in childhood and adolescence.
Espay AJ; Azzarelli B; Williams LS; Bodensteiner JB
J Child Neurol; 2001 May; 16(5):364-7. PubMed ID: 11392522
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
12. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
13. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
14. Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study.
Ozer E; Canda MS; Ulukus C; Guray M; Erbayraktar S
Tumori; 2003; 89(1):54-9. PubMed ID: 12729363
[TBL] [Abstract][Full Text] [Related]
15. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications.
Magagna-Poveda A; Leske H; Schmid C; Bernays R; Rushing EJ
Swiss Med Wkly; 2013; 143():w13895. PubMed ID: 24222652
[TBL] [Abstract][Full Text] [Related]
16. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
17. Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms.
Ruffini F; D'Atri S; Lacal PM
Int J Oncol; 2013 Jul; 43(1):297-306. PubMed ID: 23685409
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space.
Pan LX; Chen ZP; Liu YS; Zhao JH
J Neurooncol; 2005 Aug; 74(1):71-6. PubMed ID: 16078111
[TBL] [Abstract][Full Text] [Related]
19. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas.
Fukui S; Otani N; Nawashiro H; Yano A; Nomura N; Miyazawa T; Ohnuki A; Tsuzuki N; Katoh H; Ishihara S; Shima K
Brain Tumor Pathol; 2002; 19(1):23-9. PubMed ID: 12455885
[TBL] [Abstract][Full Text] [Related]
20. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
